Clinical trial
Preoperative Herceptin and Navelbine for Breast Cancer
NCT00148681 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00148681 |
|---|---|
| Title | Preoperative Herceptin and Navelbine for Breast Cancer |
| Official title | Preoperative Herceptin and Navelbine in Early Stage, HER-2 Positive Breast Cancer |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Massachusetts General Hospital Beth Israel Deaconess Medical Center Brigham and Women's Hospital |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer |
| Intervention type | Drug |
| Interventions | Herceptin, Navelbine, Doxorubicin, Cyclophosphamide, Paclitaxel |
| Enrollment | 49 |
| Start date | May 1, 2001 |
| Primary completion | May 1, 2003 |
| Completion | May 1, 2003 |
| First posted | Sep 8, 2005 |
| Last update posted | Jan 15, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: